摘要
目的:观察艾迪注射液联合化疗治疗胃癌的疗效、毒副反应及对患者免疫功能的影响。方法:将我院66例胃癌患者随机分为2组,对照组34例采用FOLFOX4方案化疗(奥沙利铂95mg·m-2静脉滴注,d1;氟尿嘧啶400mg·m-2静脉注射后600mg·m-2持续静脉滴注22h,d1～2;亚叶酸钙200mg·m-2静脉滴注,d1～2);观察组32例在化疗基础上加用艾迪注射液,每次100mL加入0.9%氯化钠注射液500mL中静脉滴注,qd,连用10d。2组均14d为1个周期,1个周期后评价疗效并比较毒副反应,同时考察对患者免疫功能的影响。结果:2组疗效无显著性差异(P>0.05);观察组胃肠道反应发生率显著低于对照组,白细胞下降程度显著轻于对照组(P<0.05);观察组化疗后T细胞免疫功能及NKT细胞活性均有显著增加(P<0.05)。结论:相比单纯化疗,艾迪注射液联合化疗治疗胃癌可降低毒副反应及对患者免疫功能的影响。
OBJECTIVE： To observe the therapeutic efficacy, toxic reaction and effect of Aidi injection combined with chemo- therapy in the treatment of gastric cancer and immunological function. METHODS： 66 cases of gastric cancer were randomly divid- ed into 2 groups. 34 cases in control group were given FOLFOX4 chemotherapy （oxaliplatin 95 mg.m^-2 i.v. d1-2, 5-FU 600 mg,m 2 i.v. for 22 h after giving 5-FU 400 mg,m^-2i.v. d1-2; calcium folinate 200 mg-m-2 i.v. dl-2）. 32 cases of observation group were ad- ditionally given Aidi injection 100 mL each time by dissolving in normal saline 500 mL per day for 10 days on the basis of chemo- therapy. A treatment course of 2 groups lasted for 14 day. Therapeutic efficacy and toxic reaction were evaluated after 1 cycle, while the effect of therapy on immunological function was detected. RESULTS： There was no significant difference in therapeutic efficacy between 2 groups （P〉0.05） ; the incidence of gastrointestinal reaction in observation group was significantly lower than in control group, and the amount of leukocyte decreased slightly （P〈0.05）. The immunological function of T cell and the activity of NKT cell in the observation group increased significantly after treatment （P〈0.05）. CONCLUSIONS： Compared with chemothera- py alone, Aidi injection combined with chemotherapy can reduce toxic reaction and influence of chemotherapy on immunological function.
出处
《中国药房》
CAS
CSCD
2012年第36期3392-3394,共3页
China Pharmacy
基金
山西省卫生厅科技攻关项目(20100130)
关键词
胃癌
艾迪注射液
化疗
疗效
免疫功能
Gastric cancer
Aidi injection
Chemotherapy
Therapeutic effect
Immunological function
